Glaxo faces new challenge over anti-ulcer drug rights
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GLAXO faces yet another challenge to its anti-ulcer drug Zantac, an early form of which comes off patent in the US at the end of next year, writes Gail Counsell.
The UK drug giant said yesterday that Novopharm, a manufacturer of generic drugs, had filed an application with the US Food and Drug Administration, to market the early form of the drug, known as Form 1, from the end of 1995. A similar application from another company is pending.
In April, Glaxo launched proceedings against Geneva Pharmaceuticals, a subsidiary of the Swiss drugs group Ciba-Geigy, and two other firms, Interchem Trading, a US chemical distributor, and Union Quimico Farmaceutica, a Spanish group, following a similar FDA application by them.
Glaxo maintains that only a later version of the drug, Form 2, has ever been prescribed, and that it is impossible to make the earlier form of the drug without infringing the patent on the later one. Form 2's patent runs until 2002.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments